Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

Citi lowered the firm’s price target on Nice (NICE) to $228 from $279 and keeps a Buy rating on the shares. The firm updated the company’s ...

Hotels ranked on industry awards, guest reviews and hotel class ratings Unbiased content created by U.S. News editors Photo ...

Nice's (NICE) stock fell about 15% premarket on Thursday after first quarter and full year 2025 outlook missed estimates.